|

Angiotensin Receptor Blockers in Aortic Stenosis

RECRUITINGPhase 4Sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Actively Recruiting
PhasePhase 4
SponsorInstitut universitaire de cardiologie et de pneumologie de Québec, University Laval
Started2020-02-01
Est. completion2027-02
Eligibility
Age20 Years – 99 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04913870

Summary

This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.

Eligibility

Age: 20 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria:

* Mild to moderate aortic stenosis (peak aortic jet velocity ≥2.5 and \<4m/s)
* Normal left ventricular ejection fraction (i.e. ≥50%)
* Systolic blood pressure \>110 mmHg
* Diastolic blood pressure \>70 mmHg

Exclusion Criteria:

* More than mild aortic or mitral regurgitation, or mitral stenosis
* Current use or documented indication for renin-angiotensin system medication or Aliskiren
* Known allergy or intolerance to angiotensin II receptor blockers (ARBs)
* Alzheimer, dementia or known non-compliant patient
* Renal dysfunction (glomerular filtration rate \<30ml/min/1.73m2)
* Chronic hyperkalemia
* Diagnosed hepatic failure, cirrhosis, hepatitis or history of hepatic impairment
* Newly diagnosed (\<2 months) or poorly controlled diabetes
* Pre-existing obstructive coronary artery disease with CCS III-IV angina or recent myocardial infarction (\<3 months)
* Pregnant or lactating women
* Patients unable to read, understand or sign research consent

Conditions3

Aortic StenosisAortic Valve StenosisHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.